Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potential.

Journal of immunotherapy (Hagerstown, Md. : 1997) - 1 Apr 2015

Cremer Christian, Vierbuchen Tim, Hein Lea, Fischer Rainer, Barth Stefan, Nachreiner Thomas

Abstract excerpt

Human cytolytic fusion proteins (hCFPs) are therapeutically efficacious recombinant polypeptides comprising a target cell-specific binding component and a human effector domain that induces apoptosis. Compared with former generations of immunotoxins, which contain immunogenic cytotoxic domains derived from bacteria or plants, hCFPs contain solely human proteins that do not induce an immune response, thus avoiding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Survival
Share to HL-60 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotoxins

Share to Macrophage Activation

Share to Macrophages

Share to Mutant Proteins

Share to Ribonuclease, Pancreatic

Share to Substrate Specificity

Source

Identifiers

PMID: 25710248
DOI: 10.1097/CJI.0000000000000053

Genes

RNH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potential.PMID 25710248Read ↗

Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo.Semantic proximity Read ↗

Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations.Semantic proximity Read ↗

Engineering Human Pancreatic RNase 1 as an Immunotherapeutic Agent for Cancer Therapy Through Computational and Experimental Studies.Semantic proximity Read ↗

Development of an engineered human enzyme for anti-vasculature immunotherapySemantic proximity Read ↗

Humanin variants aggregate to produce different fibril morphologies.Semantic proximity Read ↗

Isolation of monomeric human V(H)s by a phage selection.Semantic proximity Read ↗

A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity.Semantic proximity Read ↗

Engineering immunotoxin-equipped effector cells and evaluation in primary human immune cellsSemantic proximity Read ↗

Structural and molecular insights into the mechanism of action of human angiogenin-ALS variants in neurons.Semantic proximity Read ↗

The angiogenins: An emerging family of ribonuclease related proteins with diverse cellular functionsSemantic proximity Read ↗

Development and Characterization of a Potent Tumor Necrosis Factor-Alpha Blocking AgentSemantic proximity Read ↗

Engineered antibody CH2 domains binding to nucleolin: Isolation, characterization and improvement of aggregation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.